· Nugawi Intelligence · Strategy · 2 min read
The FDA Is Writing the Rules for Generative AI Devices. Are You in Scope?
The FDA has opened a public comment docket on how it should regulate generative-AI-enabled medical devices — with submissions due in October 2026. If your product touches clinical workflows, that deadline is closer than your next sprint review.
What the FDA Is Actually Asking
The agency’s discussion paper signals where US regulation is heading for GenAI in devices:
- Lifecycle monitoring — not “approve once, ship forever”, but evidence that you watch model behaviour in the field and can show it.
- Pre-determined change control plans — describing, before deployment, which model changes you’ll make and how you’ll validate each one. The model will change; the FDA wants the change itself to be the regulated artefact.
- Drift and degradation — how you detect when a generative model’s outputs are quietly getting worse, and what happens next.
Sound familiar? It should. The bones look a lot like the EU AI Act’s post-market monitoring obligations — similar skeleton, different teeth.
The Transatlantic Squeeze
This is where it gets uncomfortable for UK and European health-tech firms. If you sell — or plan to sell — into the US, you’re now reconciling two regimes that rhyme but don’t match:
| EU AI Act | FDA direction | |
|---|---|---|
| Scope | Risk-tiered across all AI | GenAI-enabled medical devices |
| Change management | Post-market monitoring, serious-incident reporting | Pre-determined change control plans |
| Evidence | Technical documentation, conformity assessment | Lifecycle performance data, validation per change |
| Clock | Phased obligations already in force | Comment window open now — rules forming |
A compliance story built for Brussels alone will not survive Washington, and vice versa.
The Two-Week Gap Map
This is precisely the work we do. In a focused engagement we read your AI system against both regimes and hand you three things: the delta between what you have and what each regime expects, a remediation order ranked by regulatory risk, and the documentation skeleton you’ll need whether the FDA’s final rules land hard or soft.
Don’t Wait for the Final Rule
Regulation written in January is strategy. Regulation written the week before a deadline is panic — and priced accordingly. The organisations that comment now are the ones whose constraints the final rules will quietly reflect.
Book a Discovery Sprint — we’ll scope your FDA / EU AI Act gap map in two weeks.
This article is industry analysis, not legal advice. Confirm regulatory positions with qualified counsel.